Pre-exposure prophylaxis (PrEP) has emerged as a critical tool in the global HIV prevention response. Despite its proven efficacy, global uptake of oral PrEP has been slower than anticipated, falling short of UNAIDS’ 2025 targets. However, several countries have successfully scaled up oral PrEP, and in the process learnt significant lessons, many of which they are already applying to introduce newer long-acting (LA) PrEP options such as the dapivirine vaginal ring (DVR) and injectable cabotegravir (CAB), and in planning for the introduction of the recently FDA approved twice yearly injectable lenacapavir (LEN).
This webinar aims to increase momentum around ARV-based HIV prevention by highlighting key opportunities and challenges in scaling up PrEP. Drawing on findings from AVAC’s recent report, “Getting PrEP Rollout Right This Time: Lessons from the Field” (June 2025), the session will share country-level insights and effective interventions to support PrEP adherence and uptake. It will reinforce the need for robust, context-driven strategies to accelerate equitable access to these critical prevention tools.
The specific objectives of this webinar are:
- Disseminate key findings from AVAC’s report, Getting PrEP Rollout Right This Time, with a focus on country experiences thematically analysed across the key stages of the Product Introduction Pathway.
- Share country-level evidence and insights on the introduction of new PrEP products, such as injectable cabotegravir (CAB) and the dapivirine vaginal ring (DVR) and preparations for the rollout of lenacapavir.
- Introduce an SOP to guide the adaptation of national PrEP policies for the inclusion of lenacapavir, supporting evidence-informed decision-making and implementation planning.
- Highlight effective interventions that support PrEP adherence and uptake, drawing on evidence products developed by the i2i programme.
Live translation will be available in French and Portuguese.
